Efficacy of topical isobutylamido thiazolyl resorcinol (thiamidol) compared to triple combination therapy in patients with melasma a prospective study

The trial has not begun enrolling patients

Melasma is a pigmentary disorder that affects middle aged women more commonly presents as hyperpigmented irregular macules patches on sun exposed areas like cheeks upper lip chin  nasal bridge forehead and the neck

It is a stubborn condition which is more prone to relapse  It has a complex etiology like exposure to Ultraviolet radiations pregnancy oral contraceptive pills Hormone replacement therapy etc

Various studies used multiple treatment modalities including topically applied depigmenting agents like hydroquinone alone triple combination therapy cysteamine chemical peels glycolic acid and laser therapy with none of them showing satisfactory outcomes

Thiamidol is now being identified as a new potent inhibitor of human tyrosinase enzyme

This  study titled Efficacy of Topical Isobutylamido Thiazolyl Resorcinol Thiamidol Compared to Triple Combination Therapy in patients with Melasma  over 18 months The study aims to compare the therapeutic efficacy and safety of topical Thiamidol with the conventional triple combination therapy in patients with melasma

A total of 68 patients clinically diagnosed with melasma will be randomly divided into two groups Group A  will be treated with topical Thiamidol Group B will be treated with triple combination therapy

Clinical assessment will be done by using the Modified Melasma Area and Severity Index mMASI at baseline 4 weeks 8 weeks and 12 weeks Clinical photographs will be taken at each time point under standardized conditions Data will be analyzed using paired and unpaired t tests

The primary outcome will be the change in mMASI score from baseline to 12 weeks which will indicate treatment efficacy The secondary outcomes will include the evaluation of side effects and patient tolerance to each therapy